GRAM-NEGATIVE INFECTIONS: Edited by Matteo BassettiRational approach in the management of Pseudomonas aeruginosa infectionsBassetti, Matteoa; Vena, Antonioa; Russo, Alessandroa; Croxatto, Antonyb; Calandra, Thierryc; Guery, BenoitcAuthor Information aInfectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy bInstitute of Microbiology, University of Lausanne, Lausanne, Switzerland cInfectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne Correspondence to Matteo Bassetti, Clinica di Malattie Infettive, Azienda Ospedaliera Universitaria Integrata di Udine, Piazzale Santa Maria della Misericordia 15, 33010 Udine, Italy. Tel: +39 432 55 93 99; fax: +39 432 55 93 71; e-mail: [email protected]; [email protected] Current Opinion in Infectious Diseases: December 2018 - Volume 31 - Issue 6 - p 578-586 doi: 10.1097/QCO.0000000000000505 Buy Metrics Abstract Purpose of review This review details the management of Pseudomonas aeruginosa infections covering both current and future treatment options that are and may be available for the clinicians. Recent findings Pseudomonas aeruginosa infections are a great concern in hospital-acquired infections with very limited therapeutic options. The increasing antibiotic resistance has led to a need for different treatment choices that range from the use of new antibiotics to new nonantibiotic alternative agents to kill or disarm the pathogen. Summary New molecules such as ceftolozane–tazobactam, ceftazidime–avibactam, and imipenem–relebactam have shown an adequate activity against P. aeruginosa, especially against multidrug resistance strains. Other nonantibiotic alternative treatments, such as antibodies, bacteriocins or phage therapy, have shown promising results, but future clinical studies are needed. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.